Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06585527
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study on the Safety and Efficacy of the Third-Generation Oncolytic Virus TS-2021 in the Treatment of Recurrent Malignant Glioma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant gliomaAbout 30 eligible participants with recurrent malignant glioma will
Be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy
Be followed for 1 year after the injection to complete imaging studies neurological function tests and report adverse events
Using the data obtained during the follow-up period researchers will conduct statistical analyses and evaluate the safety and efficacy of oncolytic virus TS-2021
Be intratumoral injected the TS-2021 oncolytic virus to study its safety and efficacy
Be followed for 1 year after the injection to complete imaging studies neurological function tests and report adverse events
Using the data obtained during the follow-up period researchers will conduct statistical analyses and evaluate the safety and efficacy of oncolytic virus TS-2021
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None